ID: ALA152614

Max Phase: Preclinical

Molecular Formula: C19H18BrN3O3

Molecular Weight: 416.28

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(CBr)NCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O

Standard InChI:  InChI=1S/C19H18BrN3O3/c20-13-17(24)21-12-11-16-18(25)22(14-7-3-1-4-8-14)23(19(16)26)15-9-5-2-6-10-15/h1-10,16H,11-13H2,(H,21,24)

Standard InChI Key:  RTCGTUGHCRMVNT-UHFFFAOYSA-N

Associated Targets(Human)

Cyclooxygenase 1258 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 416.28Molecular Weight (Monoisotopic): 415.0532AlogP: 2.50#Rotatable Bonds: 6
Polar Surface Area: 69.72Molecular Species: ACIDHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 3.96CX Basic pKa: CX LogP: 2.24CX LogD: 0.17
Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.58Np Likeness Score: -0.29

References

1. Vennerstrom JL, Holmes TJ..  (1987)  Preparation and evaluation of electrophilic derivatives of phenylbutazone as inhibitors of prostaglandin-H synthase.,  30  (3): [PMID:3102742] [10.1021/jm00386a020]

Source